Ambalal Sarabhai Enterprises Limited (BOM:500009)
India · Delayed Price · Currency is INR 45.69
+3.22 (7.58%)
At close: Aug 17, 2026
BOM:500009 Revenue
Ambalal Sarabhai Enterprises had revenue of 455.90M INR in the quarter ending June 30, 2026, with 13.02% growth. This brings the company's revenue in the last twelve months to 1.99B, up 1.25% year-over-year. In the fiscal year ending March 31, 2026, Ambalal Sarabhai Enterprises had annual revenue of 2.03B with 2.64% growth.
Revenue (ttm)
1.99B
Revenue Growth
+1.25%
P/S Ratio
1.76
Revenue / Employee
3.65M
Employees
104
Market Cap
3.50B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.03B | 52.02M | 2.64% |
| Mar 31, 2025 | 1.97B | 230.03M | 13.20% |
| Mar 31, 2024 | 1.74B | 32.87M | 1.92% |
| Mar 31, 2023 | 1.71B | -266.02M | -13.46% |
| Mar 31, 2022 | 1.98B | 324.75M | 19.66% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Albert David | 3.64B |
| Medico Remedies | 2.38B |
| Medicamen Biotech | 2.06B |
| Everest Organics | 1.92B |
| Gennex Laboratories | 1.78B |
| Jenburkt Pharmaceuticals | 1.69B |
| Astonea Labs | 1.48B |
| Trident Lifeline | 1.39B |
Ambalal Sarabhai Enterprises News
- 5 months ago - EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity - Benzinga